共 50 条
- [1] NEUROPSYCHOPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S12024-2 IN EARLY ALZHEIMERS-DISEASEJOURNAL OF PSYCHOPHYSIOLOGY, 1994, 8 (03) : 257 - 258DEROUESNE, CRENAULT, BGUIGUEN, BVANDERLINDEN, MLACOMBLEZ, LHOMEYER, POUSS, LNEUMAN, EMALBEZIN, MBARRANDON, SGUEZ, D
- [2] EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASEGASTROENTEROLOGY, 2021, 160 (06) : S37 - S37Sands, Bruce E.Sandborn, William J.Peyrin-Biroulet, LaurentHiggins, Peter D.Hirai, FumihitoJairath, VipulD'Haens, GeertAbreu, Maria T.Belin, RuthValderas, Elisa GomezMiller, DebraNaegeli, April N.Arora, VipinPollack, PaulTuttle, JayHibi, Toshifumi
- [3] Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in BrazilWorld Journal of Gastroenterology, 2021, 27 (02) : 208 - 223Cyrla ZaltmanRogério Serafim ParraLigia Yukie SassakiGenoile Oliveira SantanaMaria de Lourdes Abreu FerrariSender J MiszputenHeda M B S AmaranteRoberto Luiz Kaiser JuniorCristina FloresWilson R CatapaniJosé Miguel Luz ParenteMauro BafuttoOdery RamosCarolina D Gon?alvesIsabella Miranda GuimaraesJose J R da RochaMarley R FeitosaOmar FeresRogerio Saad-HossneFrancisco Guilherme Cancela PennaPedro Ferrari Sales CunhaTarcia NF GomesRodrigo Bremer NonesMikaell Alexandre Gouvea FariaMírian Perpétua Palha Dias ParenteAntónio S ScottonRosana Fusaro CaratinJuliana SenraJúlio Maria Chebli
- [4] Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in BrazilWORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (02) : 208 - 223Zaltman, CyrlaParra, Rogerio SerafimSassaki, Ligia YukieSantana, Genoile OliveiraFerrari, Maria de Lourdes AbreuMiszputen, Sender J.Amarante, Heda M. B. S.Kaiser Junior, Roberto LuizFlores, CristinaCatapani, Wilson R.Parente, Jose Miguel LuzBafutto, MauroRamos, OderyGoncalves, Carolina D.Guimaraes, Isabella Mirandada Rocha, Jose J. R.Feitosa, Marley R.Feres, OmarSaad-Hossne, RogerioPenna, Francisco Guilherme CancelaCunha, Pedro Ferrari SalesGomes, Tarcia N. F.Nones, Rodrigo BremerFaria, Mikaell Alexandre GouveaParente, Mirian Perpetua Palha DiasScotton, Antonio S.Caratin, Rosana FusaroSenra, JulianaChebli, Julio Maria
- [6] Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's DiseaseGASTROENTEROLOGY, 2014, 146 (05) : S368 - S369D'Haens, Geert R.Sandborn, WilliamColombel, Jean-FredericBrown, KurtHaviv, AsiBarkay, HadasSakov, AnatFeagan, Brian G.
- [7] The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's diseaseEXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (12) : 1383 - 1390Vorovenci, Ruxandra JuliaAntonini, Angelo
- [8] Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's diseaseJOURNAL OF CROHNS & COLITIS, 2014, 8 : S43 - S43D'Haens, G.Sandborn, W. J.Rutgeerts, P.Colombel, J. F.Brown, K.Haviv, A.Barkay, H.Sakov, A.Feagan, B.
- [9] TOFACITINIB IMPROVES CLINICAL DISEASE ACTIVITY IN A REAL-WORLD POPULATION OF PATIENTS WITH MODERATE-SEVERE ULCERATIVE COLITIS AND CROHN'S DISEASEGASTROENTEROLOGY, 2019, 156 (06) : S664 - S664Clark-Snustad, Kindra D.Singla, AnandLee, Scott D.
- [10] Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's diseaseGUT, 2006, 55 (08) : 1131 - 1137Hommes, D. W.Mikhajlova, T. L.Stoinov, S.Stimac, D.Vucelic, B.Lonovics, J.Zakuciova, M.D'Haens, G.Van Assche, G.Ba, S.Lee, S.Pearce, T.